Replimune reports 32.9-month median survival in IGNYTE trial of RP1-nivolumab in anti-PD-1-failed melanoma
PUBT · 21h ago
Share
Listen to the news
- Replimune presented 3-year overall survival follow-up from IGNYTE at the 2026 ASCO annual meeting on May 30.
- RP1 with nivolumab showed durable survival in advanced melanoma patients whose disease progressed on prior anti-PD-1 therapy.
- Benefit appeared sustained in long-term responders, supporting the regimen’s potential to extend disease control in a hard-to-treat setting.
- Safety remained manageable over extended follow-up, with no new safety concerns flagged in the update.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605300800PRIMZONEFULLFEED9729181) on May 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved